Skip to main content

SciBite - Open Intelligence on Pharmaceutical Discovery & Development



Lee Harland, is a visitor in the ChEMBL group here at EMBL-EBI, and he is collaborating with us on semantic web data integration, text-mining, target ontologies and so forth. I asked him to write a small piece for the ChEMBL-og on one of his personal projects - SciBites, and here is what he wrote......


"SciBite is a new biomedical alerting service tailored to pharmaceutically relevant questions and focused on targets, diseases and drugs. The premise is simple, right now if you're a scientist interested in say, Asthma, how can you stay on top of all the lastest developments? You can of course, set up pubmed searches, patent searches, google news searches (making sure you have remembered every possible synonym as these tools won't do that for you). What you'll get back is a stream of articles. Some relevant, many not, and you'll have to read them to actually find out. We thought there had to be a better way.. What we really wanted was a kind of Twitter for "things", where the drugs, disease and targets could each tweet relevant news, in an easily consumable (and discoverable) way. So we built SciBite.

SciBite works by continually scanning 1000s of sources including literature, patents, news feeds, blogs, databases and more. It looks at every new article and automatically tags the targets, diseases, drugs, companies and 'contexts' (such as "biomaker study", "regulatory approval", "animal model" etc), that it finds. Users can then go to the website and view information by topic, not by source. The lists can be filtered based on source or other criteria such as regulatory approval or biomarkers. Everything is available as an RSS feed so users can stay on top of latest news. Information is presented in a very visual way, making it really easy to scan new articles and identify the key topics. We also have relevancy filters to remove spurious and irrelevant news (although this will never be perfect!). Finally, our "related topics" function allows you to quickly find the targets, diseases or drugs being co-mentioned with the thing you're interested in, which is an incredibly powerful way to spot new and interesting connections.

There are a number of major content companies doing this sort of thing, and as a small (tiny) company, we cannot hope to match their levels of curation and resources. However, we believe that this sort of information should be available to everyone and so we hope that by using technology we can provide something that comes close to what the major players offer. We decided early on that as we were using a lot of public data (including ChEMBL), the site itself should be free and support these efforts. We're also making all our data and APIs freely available to any non-profit organisation expressing an interest. 

We've seen a great growth in user numbers since our very low-key launch at the start of February. Over 2000 people have used the site, and we've done hardly any advertising... Its daunting to see that many so soon, but its a great feeling to know people are finding it useful! What's there now is really just the start. The aim was to build a platform that connected news to things, which we've done. The next stages are to do much more with the data. This is one of the things I'll be exploring as part of my Visitorship with the ChEMBL group, we're looking at some interesting company-centric profiling, tracking whats going on with each organisations drugs. There's a whole lot more planned for 2012 too!

Anyone interested can use the system for free now, at http://scibite.com. I tweet as @SciBitely and our blog is at http://about.scibite.com."

Wow! Look at what is there.

Comments

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

In search of the perfect assay description

Credit: Science biotech, CC BY-SA 4.0 Assays des cribe the experimental set-up when testing the activity of drug-like compounds against biological targets; they provide useful context for researchers interested in drug-target relationships. Ver sion 33 of ChEMBL contains 1.6 million diverse assays spanning ADMET, physicochemical, binding, functional and toxicity experiments. A set of well-defined and structured assay descriptions would be valuable for the drug discovery community, particularly for text mining and NLP projects. These would also support ChEMBL's ongoing efforts towards an  in vitro  assay classification. This Blog post will consider the features of the 'perfect' assay description and provide a guide for depositors on the submission of high quality data. ChEMBL's assays are typically structured with the overall aim, target, and method .  The ideal assay description is succinct but contains all the necessary information for easy interpretation by database u